Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

elderly

LOTIS-5: loncastuximab tesirine + rituximab for elderly patients with R/R DLBCL 4:45
LOTIS-5: loncastuximab tesirine + rituximab for elderly patients with R/R DLBCL
Carmelo Carlo-Stella • 15 Jun 2023
Multi-dimensional analysis of the mutational landscape of AML 2:18
Multi-dimensional analysis of the mutational landscape of AML
Monica Cusan • 21 Mar 2023
Standard treatment of elderly patients with AML & evaluating IDH inhibitors in younger patients 3:14
Standard treatment of elderly patients with AML & evaluating IDH inhibitors in younger patients
Alan Burnett • 21 Mar 2023
ISAL session highlights: gemtuzumab & small molecule inhibitors with chemotherapy in AML and APL 2:32
ISAL session highlights: gemtuzumab & small molecule inhibitors with chemotherapy in AML and APL
Alan Burnett • 21 Mar 2023
Advances in cellular therapies for lymphoma: the value of CAR-T therapy & optimizing patient outcome 1:41
Advances in cellular therapies for lymphoma: the value of CAR-T therapy & optimizing patient outcome
Jason Westin • 11 Dec 2022
Cost-effectiveness of azacitidine and ivosidenib in elderly patients with newly diagnosed IDH1m AML 2:54
Cost-effectiveness of azacitidine and ivosidenib in elderly patients with newly diagnosed IDH1m AML
Jan Bewersdorf • 11 Dec 2022
Recent updates in HL research & the importance of improving treatment for elderly & frail patients 1:30
Recent updates in HL research & the importance of improving treatment for elderly & frail patients
Ninja Övergaard • 19 Oct 2022
Challenges for HCPs in Ireland treating multiple myeloma 0:50
Challenges for HCPs in Ireland treating multiple myeloma
Philip Murphy • 1 Sep 2022
The importance of treatment intensity in frail and elderly patients with multiple myeloma 1:16
The importance of treatment intensity in frail and elderly patients with multiple myeloma
Siobhan Glavey • 4 Nov 2022
Treatment approaches for elderly/unfit patients with AML ineligible for intensive chemotherapy 3:25
Treatment approaches for elderly/unfit patients with AML ineligible for intensive chemotherapy
Tapan Kadia • 29 Sep 2022
Biomarkers to predict outcomes in patients with myeloma treated with lenalidomide and dexamethasone 2:24
Biomarkers to predict outcomes in patients with myeloma treated with lenalidomide and dexamethasone
Bruno Paiva • 25 Aug 2022
Frailty-adjusted therapy & incorporating novel therapies in clinical practice for unfit patients 2:33
Frailty-adjusted therapy & incorporating novel therapies in clinical practice for unfit patients
Gordon Cook • 26 Aug 2022
Treatment strategies for frail and elderly myeloma patients 1:34
Treatment strategies for frail and elderly myeloma patients
Salomon Manier • 27 Aug 2022
IFM 2018-02: ixazomib + daratumumab in elderly frail patients with R/R multiple myeloma 4:23
IFM 2018-02: ixazomib + daratumumab in elderly frail patients with R/R multiple myeloma
Xavier Leleu • 10 Jun 2022
Highlights in AML: quizartinib in elderly patients & in frontline FLT3-mutated AML 0:51
Highlights in AML: quizartinib in elderly patients & in frontline FLT3-mutated AML
Tapan Kadia • 10 Jun 2022
VEN-A-QUI: low-dose cytarabine or azacitidine+venetoclax and quizartinib in older patients with AML 4:13
VEN-A-QUI: low-dose cytarabine or azacitidine+venetoclax and quizartinib in older patients with AML
Juan Miguel Bergua-Burgues • 10 Jun 2022

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals